Jupiter Topco LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 704,213 shares of the biopharmaceutical company

Equitable Holdings Inc. bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 126,744 shares of the biopharmaceutical compa

Coastal Bridge Advisors LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm purchased 56,768 shares of the biopharmaceutical company

Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,068 shares of the biopha

On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]

Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]